Previous studies have demonstrated that naringenin interacts with estrogen receptors, promotes apoptosis, inhibits enzymes associated with cell survival and proliferation, and decreases the expression of cyclin-dependent kinases in CRC cells, indicating its potential as a therapeutic agent for CRC [52]. The gene discussed is ESR1; the disease is colorectal carcinoma.